Alzheimer's Treatment: What the At-Home Leqembi Starting Dose Means for Clinicians

If you treat patients with early Alzheimer's disease, you've probably already heard the news. In July 2026, the FDA approved a subcutaneous starting dose for Leqembi (lecanemab-irmb), branded as Leqembi Iqlik, with a launch planned for late August 2026. For the first time, patients can begin anti-amyloid treatment with a weekly at-home injection instead of biweekly hour-long IV infusions.

That's a genuinely significant clinical development. It's also a headline that sounds simpler than it is once you look at what happens on the billing side of your practice.

Moving a drug from an infusion suite to a patient's kitchen table changes more than delivery. It can change which benefit pays for it, who submits the claim, what prior authorization looks like, and how you get paid for the clinical oversight that still has to happen even when the drug is self-administered. That last part is where practices will get tripped up over the next several months.

This article covers what the approval actually changes, what stays the same clinically, and where your billing workflows need to adapt so you're not chasing denials in Q4.

What Actually Changed: The FDA Approval Explained

Before this approval, Leqembi had two delivery paths. Patients started on intravenous infusions, dosed at 10 mg/kg every two weeks, administered in a clinical setting over roughly an hour. After 18 months of that IV initiation phase, patients had the option to transition to a subcutaneous maintenance dose, delivered weekly via autoinjector, which the FDA had already approved back in August 2025.

The new approval removes the 18-month IV requirement for patients who want to start on subcutaneous dosing. Under the new regimen, initiation is 500 mg once weekly, given as two 250 mg injections, each taking about 15 seconds. Clinical data presented at the Alzheimer's Association International Conference showed the subcutaneous starting dose performs comparably to the IV starting regimen, with a generally consistent safety profile.

In plain terms: a newly diagnosed patient who meets the clinical criteria can now potentially skip the infusion chair altogether and start treatment with a weekly self-injection at home, administered by themselves or a caregiver.

This is the first anti-amyloid Alzheimer's therapy approved for at-home initiation. That's a meaningful shift in how early Alzheimer's care can be delivered, and it's likely to open the door for similar delivery innovations in the disease-modifying therapy space going forward.

Why This Matters Clinically, Not Just Operationally

It's worth pausing on why this change is being welcomed so warmly by advocacy groups and clinicians alike, because it's not just about convenience.

1. Reduced infusion center burden. Infusion capacity has been a real bottleneck for practices trying to scale anti-amyloid treatment. At-home dosing takes pressure off scheduling and staffing.
2. Lower caregiver burden. For families managing transportation, work schedules, and the logistics of getting a person with cognitive impairment to biweekly appointments, this is a substantial quality-of-life improvement.
3. Access for rural and underserved patients. Patients who live far from infusion centers, or in areas without one at all, now have a realistic path to treatment they may not have had before.
4. A signal for the future of combination therapy. As the Alzheimer's Drug Discovery Foundation has noted, long-term multi-drug regimens for Alzheimer's are only sustainable if individual therapies can be delivered at home. This approval is being read as an early building block for that future.

None of this changes the underlying clinical risk profile of the drug, though, which is exactly why the workup and monitoring requirements are still very much intact.

The Diagnostic and Monitoring Requirements Haven't Gone Away

This is the point that's easy to lose in the "at-home" framing. Self-administered dosing does not mean self-managed care.

Patients still need:

1. A confirmed clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer's disease
2. Confirmed presence of amyloid beta pathology, typically through PET imaging or CSF biomarker testing, prior to starting treatment
3. A baseline brain MRI within one year of initiation, with periodic MRI monitoring during the early treatment period to screen for amyloid-related imaging abnormalities, or ARIA
4. Enhanced clinical vigilance during roughly the first 14 weeks of treatment, when ARIA risk is highest

The delivery route changed. The clinical oversight obligations didn't. Practices need to keep this front and center when they're designing at-home protocols, because the visits for imaging, labs, and clinical check-ins are still billable, still necessary, and still need to be coded and documented correctly, separate from the drug administration itself.

Where the Real Complexity Lives: Billing and Reimbursement

Here's where this gets genuinely interesting from a revenue cycle standpoint, and where most of the operational friction is going to show up.

When Leqembi is given as an IV infusion, it's billed under HCPCS code J0174, submitted through the medical benefit, typically Medicare Part B for eligible patients. That claim includes the drug itself, the infusion administration CPT code, and is subject to the JW or JZ wastage modifier requirements CMS made mandatory for single-dose vial drugs. Medicare reimburses at ASP plus 6 percent, with the standard 20 percent Part B coinsurance applying to the patient.

Self-administered subcutaneous Leqembi Iqlik works differently. According to payer medical policy documentation, including UnitedHealthcare's coverage policy, self-administered Leqembi Iqlik is generally obtained under the pharmacy benefit rather than the medical benefit, unless a specific plan document states otherwise. That's a meaningful distinction, and it's the single biggest operational change practices need to prepare for.

Medical Benefit vs. Pharmacy Benefit: The Shift That Catches Practices Off Guard

If you've built your workflow around buy-and-bill for infusion drugs, at-home Leqembi Iqlik doesn't fit that model in the same way. Here's what changes when a drug moves to the pharmacy benefit:

1. Dispensing shifts to specialty pharmacy. Instead of your practice purchasing the drug and billing for it directly, the prescription typically routes through a specialty pharmacy, which dispenses the autoinjector to the patient.
2. Prior authorization workflow changes. Pharmacy benefit prior authorizations often run through a different system, different forms, and sometimes a different internal team than medical benefit prior auths.
3. No more buy-and-bill margin. Practices that relied on the administration fee and any margin from medical benefit drug billing need to recognize that revenue stream looks different when the patient is self-injecting at home.
4. Your clinical oversight still needs its own billing pathway. The office visits, MRI monitoring, and evaluation and management work tied to starting and managing a patient on lecanemab don't disappear. They need to be captured and billed correctly, independent of the drug claim.

This is exactly the kind of transition where practices either adapt their front-end verification and prior authorization processes quickly, or they start seeing claim denials and delayed starts that frustrate both clinicians and patients.

Medicare, Medicare Advantage, and the CED Registry Requirement

Medicare coverage for anti-amyloid monoclonal antibodies, including Leqembi, still operates under CMS's National Coverage Determination 200.3, structured as Coverage with Evidence Development. Under this NCD, Medicare covers FDA-approved monoclonal antibodies targeting amyloid for patients with a clinical diagnosis of MCI due to Alzheimer's disease or mild AD dementia, both with confirmed amyloid pathology, as long as the treating clinician participates in a CMS-approved registry, such as the Alzheimer's Network for Treatment and Diagnostics or the CMS National Patient Registry.

This registry requirement applies regardless of whether the drug is delivered by IV or subcutaneous injection. Practices transitioning patients to at-home dosing still need to maintain registry enrollment and data submission to keep claims compliant.

Medicare Advantage plans generally follow the NCD as a coverage floor, but plan-specific prior authorization criteria, timelines, and site-of-care requirements vary. Some payers have been actively revising their utilization management criteria as clinical practice evolves. For example, at least one regional payer's June 2026 policy update removed a prior requirement around documenting ApoE4 genotype testing discussions before initiation, which is a good reminder that these policies are living documents, not one-time reads.

The 2026 Medicare Part D and Medicare Prescription Payment Plan annual out-of-pocket cap of 2,100 dollars is also relevant here, since a self-administered drug billed through the pharmacy benefit may fall under Part D cost-sharing rules for eligible patients, which is a different financial conversation with families than the Part B coinsurance structure they may be used to.

Commercial Payers and Medicaid: What to Expect

1. Commercial payers are increasingly publishing separate medical necessity policies for IV versus self-administered Leqembi, often specifying that the subcutaneous starting dose is a pharmacy benefit product. Always verify the specific plan document rather than assuming a blanket policy.
2. Medicaid coverage and reimbursement for Leqembi varies significantly by state, since each state Medicaid program sets its own eligibility standards and scope of coverage. Don't assume your state's existing IV coverage policy automatically extends to the at-home subcutaneous starting dose.
3. Prior authorization documentation across most payers will still expect evidence of the AD diagnosis, confirmed amyloid pathology, and a monitoring plan, even when the drug itself moves to the pharmacy benefit.

Common Billing and Coding Mistakes to Avoid

1. Assuming the drug bills the same way regardless of route. IV Leqembi under J0174 and self-administered Leqembi Iqlik are not interchangeable on a claim. Confirm benefit type before submission.
2. Skipping benefit verification before the first prescription. Because Iqlik often routes through pharmacy benefit and specialty pharmacy, a medical benefit eligibility check alone won't tell you what you need to know.
3. Forgetting JW or JZ modifiers on IV claims. These remain mandatory for single-dose vial claims and are a common source of denials or recoupment audits when omitted or applied incorrectly.
4. Letting registry enrollment lapse during the transition. If a patient moves from IV to at-home dosing, or starts directly on the subcutaneous regimen, registry participation requirements under the CED framework still apply.
5. Under-coding the clinical oversight visits. Practices sometimes bill for the drug and the infusion but underbill or forget to separately document the evaluation and management work tied to ARIA monitoring, MRI review, and treatment planning, especially once the drug itself is no longer generating a facility claim.
6. Not updating patient financial counseling scripts. Families who budgeted for Part B coinsurance may be surprised by different cost-sharing under a pharmacy benefit and Part D structure. Getting ahead of that conversation avoids collections friction later.

Actionable Steps for Practices Preparing for the Transition

1. Audit your current Leqembi patient panel and flag which patients are candidates for the at-home starting dose versus those already established on IV therapy.
2. Confirm benefit type for each payer your practice contracts with before prescribing Leqembi Iqlik as a starting dose, since medical versus pharmacy benefit routing directly affects your workflow.
3. Build a distinct prior authorization pathway for pharmacy benefit submissions, separate from your existing medical benefit infusion drug process.
4. Coordinate early with specialty pharmacies your patients are likely to use, so you understand their intake requirements and turnaround times.
5. Keep registry documentation current for every patient on anti-amyloid therapy, regardless of delivery route, to stay compliant with the CED framework.
6. Train front desk and billing staff on the distinction between J0174 IV claims and pharmacy benefit self-administered claims, so eligibility checks are done correctly the first time.
7. Separate your coding for oversight visits from the drug claim itself, making sure ARIA monitoring, MRI review, and follow-up evaluation and management visits are captured on their own claims with appropriate documentation.
8. Update patient and caregiver financial counseling materials to reflect potential differences in out-of-pocket costs between IV and at-home dosing pathways.

Expert Recommendations

Neurology and health policy voices who welcomed this approval have consistently framed it as an accessibility win rather than a clinical simplification. That framing matters for how practices should approach implementation. The safest posture is to treat the at-home starting dose as a new administrative pathway layered on top of the same clinical rigor, not a shortcut around it.

Practices that have successfully scaled infusion-based anti-amyloid programs tend to share a few habits: they verify benefits before every new therapy start, they keep a dedicated staff member or team tracking payer policy updates for this drug class specifically, and they treat registry compliance as a non-negotiable part of the workflow rather than an afterthought. Those same habits translate directly to managing the at-home pathway well.

If your practice doesn't have the internal bandwidth to build and maintain separate medical and pharmacy benefit workflows for a drug this operationally complex, that's a reasonable moment to bring in outside revenue cycle expertise rather than absorbing avoidable denials while your team learns by trial and error.

Frequently Asked Questions

1. What is the difference between Leqembi and Leqembi Iqlik? Leqembi refers to the intravenous formulation of lecanemab, administered by infusion in a clinical setting. Leqembi Iqlik is the subcutaneous autoinjector formulation, now approved for both maintenance dosing and, as of July 2026, at-home starting dose initiation.

2. Can any patient start treatment with the at-home Leqembi Iqlik dose? Only patients who meet the FDA-approved clinical criteria for early Alzheimer's disease, meaning mild cognitive impairment due to AD or mild AD dementia with confirmed amyloid pathology, are candidates. The diagnostic workup requirements have not changed with this approval.

3. Does moving to at-home dosing eliminate the need for MRI monitoring? No. Baseline MRI and periodic monitoring for amyloid-related imaging abnormalities remain part of standard clinical practice for patients on lecanemab, regardless of delivery route.

4. How is Leqembi Iqlik billed compared to IV Leqembi? IV Leqembi is typically billed under the medical benefit using HCPCS code J0174. Self-administered Leqembi Iqlik is generally billed under the pharmacy benefit and dispensed through specialty pharmacy, according to payer coverage policy documentation. Practices should confirm this with each specific payer.

5. Does Medicare cover the at-home Leqembi starting dose? Medicare coverage for anti-amyloid monoclonal antibodies, including Leqembi in any delivery form, operates under CMS's Coverage with Evidence Development framework, which requires patients to meet diagnostic criteria and clinicians to participate in an approved registry.

6. What is Coverage with Evidence Development and why does it matter for billing? Coverage with Evidence Development, or CED, is the CMS framework under which Medicare covers this drug class conditionally on registry enrollment and data submission. Failing to maintain registry compliance can jeopardize claim payment.

7. Will patients pay differently out of pocket for at-home Leqembi versus IV infusions? Potentially, yes. A pharmacy benefit and Part D cost-sharing structure can differ from Part B coinsurance, so practices should proactively discuss this with patients and families rather than assuming costs stay the same.

8. Do practices still get reimbursed for clinical oversight if the patient is self-injecting at home? Yes, but that reimbursement comes through properly coded and documented office visits, imaging review, and evaluation and management services, separate from any drug claim, since the practice is no longer billing for infusion administration in the at-home model.

9. When did the FDA approve the at-home Leqembi starting dose? The FDA approved the subcutaneous starting dose on July 13, 2026, with a U.S. commercial launch planned for late August 2026.

10. Where can I find official guidance on Medicare coverage for Leqembi? CMS maintains coverage information under National Coverage Determination 200.3 on cms.gov, and additional plain-language guidance is available through Medicare.gov and the Alzheimer's Association.